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The acute treatment of mice with an ethanolic extract from the seed pod of Dioclea grandiﬂora (EDgP) at doses of 75, 150
and 300mg/kg by intraperitoneal administration produced a signiﬁcant antinociceptive eﬀect as displayed by the acetic acid-
induced writhing test and the formalin test. The antinociception was observed through the ﬁrst (neurogenic pain) and second
(inﬂammatory pain) phases in the formalin test. The hot plate test did not show an increase in the antinociceptive latency whereas
the motor performance was aﬀected by the administration at 300mg/kg at the beginning (30minutes) of the observation period
but not at later periods (60 and 120minutes). These results suggest that EDgP has a central antinociceptive action and a possible
anti-inﬂammatory activity in mice.
1.Introduction
Dioclea grandiﬂora Mart. Ex. Benth (Leguminosae), popu-
larly known as “mucun˜ a”, “mucun˜ a-de-caroc ¸o”, and “olho-
de-boi”orbull’seye,isavinethatgrowsinthe“caatinga”and
“cerrado” regions of Northeastern Brazil. In folk medicine,
the seed and root bark of this plant have been widely used
to treat prostate disorders and kidney stones [1]. Previous
studies reported a signiﬁcant central nervous system (CNS)
activity of the chloroformic (CHCl3) and ethanolic extract
obtainedfromthedriedrootbark[2]andthehydroalcoholic
extract from the seeds of D. grandiﬂora [3].
Phytochemical investigations have shown the presence
of various substances in this plant. For instance, two new
ﬂavanones, dioclein [4] and dioﬂorin [5], and a new
dihydroﬂavonol, dioclenol [6], were isolated from the CHCl3
soluble portion of the ethanolic root bark extract. Subse-
quently, paraibanol, agrandol, and diosalol were also isolated
from the root bark of this plant [7]. Its major constituent,
dioclein, was reported to have signiﬁcant analgesic eﬀect
in rodents [2] and a potent vasorelaxant endothelium-
dependenteﬀectintherataorta[8].Later ,apharmacological
screening revealed the antinociceptive activity of dioclenol
and dioﬂorin in mice [9].
It is evident from the literature and previous investiga-
tions that D. grandiﬂora possesses analgesic activity, namely,
theseedandrootbark.Theaimofthisstudywastoassessthe
antinociceptive activity of a diﬀerent part of this plant, that
is, the seed pod, using chemical and thermal models of acute
pain in mice.
2.MaterialandMethods
2.1. Plant Material and Preparation of Extract. Aerial parts
of D. grandiﬂora were collected in Santa Rita, Para´ ıba, Brazil2 Journal of Biomedicine and Biotechnology
andauthenticatedintheLauroPiresXavier(JPB)Herbarium
oftheFederalUniversityofPara´ ıba(UFPB),whereavoucher
specimen registered under the number 4440-JPB, MO is
deposited. The seed pod was dried in an oven at 40
◦C, and
subsequently powdered (135.14g) and extracted with 70%
ethanol/water (v/v%) for 72 hours in a Soxhlet apparatus.
The extract was then concentrated using a rotary evaporator
and a dry solid was obtained, corresponding to a yield of
4.70%.
2.2. Animals. Male Swiss mice (Mus musculus) weighing 30–
40g were obtained from the vivarium of the Laboratory
of Pharmaceutical Technology of UFPB, where they were
born and bred. The animals were housed under standard
laboratory conditions, with a 12-hour light/12-hour dark
photoperiod, with the light period beginning at 06:00 hour.
They were fed on rat chow pellets and received water ad
libitum. The room temperature was kept at 23 ± 1◦Ca n d
all experiments were conducted between 10:00 and 16:00
hour. The experimental protocol was approved by the Ethics
Committee of the Laboratory of Pharmaceutical Technology
ofUFPB(protocolnumber0404/08).Thenumberofanimals
usedinthetestsaswellastheintensityofnoxiousprocedures
was kept to a minimum considered necessary to demonstrate
the eﬀects of the treatments.
2.3.NociceptiveTests. Foreachtest,theanimalswereselected
at random and divided evenly into ﬁve groups of 10 animals
to be used as follows. All animals were brought to the test
room at least 1 hour prior to the experiments and were not
tested more than once.
2.3.1. Writhing Test. The antinociceptive activity was
assessed by the acetic acid abdominal constriction test
(writhing test), a chemical visceral pain model induced by
intraperitoneal (i.p.) injection of acetic acid, that consists
of a constriction of the abdominal muscle together with
an elongation of the body and a stretching of the hind
limbs [10]. The animals were injected i.p. with 10mL/kg
of 0.8% (v/v solution) acetic acid after 30 minutes of i.p.
administration of morphine (6mg/kg), used as positive
control, or EDgP at the dose levels of 75, 150, and 300mg/kg
of body weight. Animals injected i.p. with the same volume
of distilled water (10mL/kg) were used as the control group.
Ten minutes after the administration of the acetic acid,
pairs of mice were placed in separate boxes and the number
of abdominal writhes was counted for 15 minutes. The
antinociceptive activity was expressed as the reduction in
the number of abdominal writhes when compared to the
morphine-treated and control animals.
2.3.2. Formalin Test. The method used was similar to that
described previously by Hunskaar [11]. This test consists
in inducing nociception in mice by an injection with 20µL
of 2.5% formalin solution (0.92% formaldehyde) under
the dorsal surface skin of the right hind paw. Following
intraplantar injection of formalin, pairs of mice were placed
in separate glass recipients provided with mirrors to enable
a complete view of the nociceptive behavior. A cumulative
scoring of episodes of hind paw licking was monitored
and taken as nociceptive response. Two periods of licking
activity were considered. The ﬁrst period, known as early
or ﬁrst phase (neurogenic pain), started immediately after
the formalin injection and lasted 5 minutes. The second
period, known as late or second phase (inﬂammatory
pain), occurred 15–30 minutes after formalin injection. The
animals were injected i.p. with morphine (10mg/kg), used as
positive control, or EDgP at the dose levels of 75, 150, and
3 0 0 m g / k go fb o d yw e i g h t3 0 m i n u t e sb e f o r et h ef o r m a l i n
test. Animals injected i.p. with the same volume of distilled
water (10mL/kg) were used as the control group.
To determine the participation of opioid receptors, the
eﬀect of the opioid antagonist naloxone on the antinocicep-
tiveactivityofD. grandiﬂora seedpodwasassessed.Naloxone
was injected 15 minutes prior to the administration of the
test drug at a dose of 300mg/kg and morphine (10mg/kg) in
two groups of 10 mice.
2.3.3. Hot-Plate Test. This test was used to measure response
latencies according to the method described previously
[12]. The animals were placed individually on the hot-plate
warmed to 55 ± 1◦C and the latencies (in seconds), which
is the time elapsed until the appearance of a reaction to
the thermal stimulus (lifting or licking of the paws), were
recorded as an index of nociception. A cut-oﬀ time was set
at 30 seconds (maximal latency) to minimize injury to the
animals’ paws. Approximately 1 hour before the experiment,
the reaction time(s) for each mouse was determined and
mice with baseline latencies of more than 10 seconds were
eliminated from the study. The animals were injected i.p.
withmorphine (10mg/kg),usedaspositive control,orEDgP
at the dose levels of 75, 150, and 300mg/kg of body weight.
Control animals received i.p. the same volume of distilled
water (10mL/kg). The tests were performed at 30, 60, and
120 minutes after the respective treatments.
2.4. Toxicity Tests
2.4.1. Acute Toxicity Test (LD50). Groups of mice (n =
10) were separately injected i.p. with 250, 500, 1000, and
2000mg/kg of seed pod extract to ﬁnd the dose that kills
50% of the animals, which were observed for 14 days after
treatment.
2.4.2.MotorPerformanceTest(rota-rod). Thepossibleoccur-
rence of nonspeciﬁc eﬀects of D. grandiﬂora, such as muscle-
relaxation or sedation, was assessed in mice submitted to
the rota-rod test [13]. Motor performance was measured
as time spent walking on a rotating rod (7rpm) during 3-
minute trials (rota-rod Ugo Basile mod. 7750). To this eﬀect,
miceweresubmittedtoapreselection24hoursbeforetesting
and only those which remained on the revolving bar of the
rota-rod for 5 minutes were selected. Motor performance
was evaluated immediately before (basal), 30, 60, and 120
minutes after i.p. injection of D. grandiﬂora ethanolic extract
(300mg/kg) or distilled water (10mL/kg).Journal of Biomedicine and Biotechnology 3
2.5. Statistical Analysis. T h ed a t aw e r ee x p r e s s e db ym e a n
± standard error (S.E.M.) (except DL50) and were analyzed
for statistical signiﬁcance using one-way analysis of variance
(ANOVA) followed by Bonferroni’s multiple comparison
test or Student’s t-test depending on the case. The tests
were performed using GraphPad Prism version 4.00 for
Windows, GraphPad Software, San Diego California USA,
http://www.graphpad.com/.T h ed i ﬀerence between groups
was considered signiﬁcant when P<. 05. DL50 was
calculated using probit analysis of SPSS statistical program.
3. Results
3.1. Writhing Test. The results obtained with the writhing
test are given in Table 1. EDgP inhibited the intensity of
aceticacid-inducedvisceralnociceptiveresponseafterthei.p.
administration of all three doses (75, 150, and 300mg/kg
i.p.). The animals treated with morphine (6mg/kg) were
used as positive control, which showed signiﬁcant reduction
in the number of abdominal constrictions (writhes). In
comparison with the control group, this response was
reduced in 91.9%, 87.4%, and 97.8%, in presence of 75,
150, and 300mg, respectively. The maximal inhibition of
acetic acid-induced nociception was produced by the highest
dose tested (300mg/kg), while the morphine-treated group
showed a 94.6% reduction in the nociception inhibition
response.
3.2. Formalin Test. Table 2 shows the results obtained with
the formalin test. The treatment of mice with EDgP (75,
150, and 300mg/kg i.p.) resulted in a signiﬁcant inhibition
of the formalin-induced licking in the neurogenic (ﬁrst
phase)painandtheinﬂammatory(secondphase)painofthe
formalin test. The most signiﬁcant antinociceptive response
was observed on the second phase at 150mg/kg dose of
the extract, which reduced 100% of the formalin-induced
licking response, followed by the 300mg/kg (87.6%) and
75mg/kg (81.2%) doses and the morphine-treated group
(74%). The treatment of animals with morphine (10mg/kg
i.p.) inhibited the induced-licking in the neurogenic pain
(61%) more eﬃciently thanthe D. grandiﬂora extract(45.7%
at 75mg/kg, 58.6% at 150mg/kg and 49.3% at 300mg/kg).
As shown in Table 2, prior treatment with the opioid
receptor antagonist naloxone (6mg/kg i.p.) fully blocked the
antinociceptive activity of morphine, but failed to prevent
the antinociceptive response in mice treated with the extract
at the dose of 300mg/kg. Instead, the pretreatment with
naloxone augmented the antinociception by the extract in
both phases of the formalin test.
3.3. Hot Plate Test. The results in Table 3 show that the
treatment of mice with morphine (10mg/kg i.p.) increased
the latency response in the hot plate test at 30, 60 and 120
minutes after treatment. On the other hand, EDgP did not
signiﬁcantly inﬂuence the reaction time of the animals to the
hot plate at doses of 75, 150 and 300mg/kg in any of the
analyzed periods.
3.4. Acute Toxicity Test. The 250mg/kg dose of the extract
did not cause the death of any treated animal, whereas the
500, 1000, and 2000mg/kg doses killed 10%, 90%, and 100%
of the treated animals, respectively. The deaths occurred
within ﬁve days of the 14-day observation period. Therefore,
thesedataindicatethattheLD50forthisextractis753mg/kg
i.p. (95% conﬁdence limits: 595–929mg/kg i.p.).
3.5. Motor Performance Test (rota-rod). A signiﬁcant reduc-
tion in motor activity of mice was observed at 30 minutes
after treatment with EDgP at a dose of 300mg/kg i.p. (148.3
± 11.2 seconds) when compared to control values (176.4 ±
1.9 seconds). No signiﬁcant impairment in motor activity
was detected at 60 minutes (C: 178.6 ± 1.4 seconds; T: 174
± 2.54 seconds) and at 120 minutes (C: 171.9 ± 7.4 seconds;
T: 179.7 ± 0.3 seconds) after treatment with the extract.
4. Discussion
Accumulating pharmacological data indicate that plants are
a substantial source of active compounds capable of exerting
potential therapeutic activity in the organism. For instance,
D. grandiﬂora, a plant traditionally used for treating kidney
andprostatediseases[1],isknowntohavesigniﬁcantactivity
on the central nervous system [2]. The phytochemical
analysis of seeds and root bark of this plant led to the
isolation and identiﬁcation of various substances, namely
dioclein, dioclenol, and dioﬂorin, which have been reported
to have antinociceptive activity in rodents [4–6].
The present study demonstrates that EDgP, adminis-
tered systemically to mice, displayed marked antinociceptive
action, according to two diﬀerent models of nociception
(aceticacid-inducedwrithingreactionandformalin-induced
licking), and provides some evidence on the mechanism
implicated in this eﬀect.
The acetic acid-induced writhing test in mice is an
eﬃcient nociceptive model for the screening of analgesic
and anti-inﬂammatory drugs and is also regarded as a
useful procedure to assess visceral inﬂammatory pain [14,
15]. In this study, EDgP signiﬁcantly reduced the acetic
acid-induced abdominal writhes in mice. However, the
eﬀect was not dose dependent as the doses used (75, 150,
and 300mg/kg) produced similar responses in the treated
animals (i.e., inhibitory eﬀect). This ﬁnding supports the
results obtained by previous works that demonstrated the
analgesic eﬀect of seeds and root bark of D. grandiﬂora in
rodents [2, 9].
Additionally, a signiﬁcant antinociceptive eﬀect of EDgP
was observed in the formalin test, a reliable model of
nociception that can be used to investigate the possible
mechanism of antinociceptive action of new analgesic drugs.
This test comprises two excitatory phases and one inhibitory
interphase of the nociceptive response by employment of
tonic stimulus [16]. The ﬁrst phase (neurogenic pain)
involves the direct stimulation of sensorial aﬀerent C-ﬁbers
by formalin, while the second phase (inﬂammatory pain)
involves a peripheral inﬂammatory process and is believed
to arise from nociceptive spinal neuron hyperactivity [17,4 Journal of Biomedicine and Biotechnology
Table 1: Eﬀect of EDgP on acetic acid-induced writhings in mice.
Treatment Dose (mg/kg, i.p.) Number of writhings Inhibition (%)
Control (10 mL/kg, i.p.) 22.3 ± 3.1
D. grandiﬂora
75 1.8 ± 1.4∗ 91.9
150 2.8 ± 2.2∗ 87.4
300 0.5 ± 0.5∗ 97.8
Morphine 6 1.2 ± 1.2∗ 94.6
Values are mean ± S.E.M. (n = 10). ∗P<. 001 versus control, Bonferroni test.
Table 2: Eﬀect of EDgP on formalin-induced licking in mice.
Treatment Dose Paw licking (s)
(mg/kg, i.p.) Early phase (0–5 minutes) Inhibition (%) Late phase (15–30 minutes) Inhibition (%)
Control (10mL/kg i.p.) 85.8 ± 7.6 233.9 ± 23.6
D. grandiﬂora
75 46.6 ± 6.5∗ 45.7 44.0 ± 27.5∗ 81.2
150 35.5 ± 5.3∗ 58.6 0.0 ± 0.0∗ 100
300 43.5 ± 5.0∗ 49.3 29.0 ± 27.9∗ 87.6
Morphine 10 33.5 ± 4.6∗ 61.0 60.7 ± 24.8∗ 74.0
Naloxone 6
+
D. grandiﬂora 300 47.1 ± 4.3∗ 45.1 4.9 ± 4.9∗ 97.9
Morphine 10 69.2 ± 8.0 19.3 246.3 ± 30.5 0
Values are mean ± S.E.M. (n = 10). ∗P<. 001 versus control, Bonferroni test.
18]. Therefore, the biphasic pain-related behaviors, such as
licking, seem to be associated with two distinct mechanisms.
One mechanism involves the ﬁrst phase, which starts imme-
diately after formalin injection and lasts only a few minutes;
the other mechanism comprises the second phase, starting
15 min after formalin injection and lasting at least for 60
min. The inﬂammatory process depends on the sequential
activation of various mediators and has been correlated with
the increase of prostaglandin production, cyclo-oxygenase
(COX) induction, and nitric oxide release [18, 19]. It is
well established that both phases of the formalin test can
be inhibited by centrally acting drugs, whereas peripherally
acting drugs, such as aspirin, only inhibit the second phase
[20]. The outcome of this research showed that, on the
second phase, EDgP produced a higher antinociceptive
response than that displayed by morphine, particularly at
the dose of 150mg/kg. Thus the antinociceptive eﬀects of D.
grandiﬂora extract in the writhing test and in both phases of
the formalin test not only suggest a central (neurogenic) and
peripheral (inﬂammatory) action, but also imply that this
extract exerts an anti-inﬂammatory activity.
It is known that tissue damage is associated with the
release of inﬂammatory nociceptors [21]. One of the main
concerns in nociception studies has been the search for
alternative opioid-like drugs that can act at opioid receptors
outside the CNS with the purpose of avoiding the common
side eﬀects, such as tolerance and dependence, of central
acting drugs [22, 23]. Opioids, such as morphine, display
peripheral antinociceptive responses under conditions of
inﬂammation [24]. In this study, as the antinociception of
EDgP was comparable to that of morphine, the participation
of opioid receptors was assessed by use of the selective
antagonist naloxone in the formalin test. Naloxone (6mg/kg
i.p.) did not reverse the antinociceptive eﬀect of EDgP;
instead, it increased it at the dose level of 300mg/kg while
it considerably reduced morphine analgesic eﬀect. Similarly,
a higher dose of naloxone (10mg/kg) has been reported
to produce no eﬀect in the formalin test in rats [25]. The
data of this research indicate that central or peripheral
active endogenous opioids do not seem to be mediating the
antinociceptive eﬀect of EDgP in the formalin test.
In the thermal model for nociception (hot plate test), the
results show that, although the pain threshold reaction of the
animals increased after the administration of EDgP at the
doses of 75, 150, and 300mg/kg in all analyzed periods, the
latencyresponseswerenotconsideredstatisticallysigniﬁcant.
On the other hand, morphine (10mg/kg) produced a signif-
icant antinociceptive eﬀect in all observation periods when
compared to control values. Similar ﬁndings were observed
in previous works to the extent that several compounds
(i.e., NS 398–COX-2 inhibitor-indomethacin and other
non-steroid anti-inﬂammatory drugs) failed to produce a
signiﬁcant antinociceptive eﬀect on animals submitted to
the hot plate test [26]. This suggests that the substances
present in EDgP are particularly eﬀective in relieving painful
inﬂammatory states.
One possible mechanism involved in the nociceptive
response is the transient receptor potential vanilloid 1
(TRPV1), a nonselective cation channel which is known to
play an important role in the transmission and modula-
tion of pain as well as the integration of diverse painful
stimuli [27]. The TRPV1 receptor is considered a molecular
integrator of various physicochemical noxious stimuli such
as the formalin-induced acute nocifensive behavior [28].Journal of Biomedicine and Biotechnology 5
Table 3: Eﬀect of EDgP on the hot plate test in mice.
Treatment Dose Reaction time (s)
(mg/kg, i.p.) 30 minutes 60 minutes 120 minutes
Control (10mL/kg, i.p.) 7.2 ± 1.3 8.3 ± 1.1 6.5 ± 0.9
D. grandiﬂora
75 11.8 ± 2.8 10.7 ± 2.2 8.0 ± 1.3
150 9.2 ± 1.6 11.8 ± 1.8 10.1 ± 1.7
300 12.2 ± 1.8 10.0 ± 2.0 9.6 ± 1.6
Morphine 10 18.5 ± 2.5∗ 11.5 ± 0.8∗ 11.0 ± 1.7∗
Values are mean ± S.E.M. (n = 10). ∗P<. 05 versus control.
Upon tissue damage and the consequent inﬂammation,
inﬂammatory mediators increase the sensitivity of TRPV1 to
the noxious stimuli. Antagonists have been shown to block
TRPV1 activity, thus reducing pain. In rats, for instance,
TRPV1 antagonists were eﬀective in reducing nociception
from inﬂammatory and neuropathic pain models [29]. In
this work, the evidence is suggestive of an antinociceptive
eﬀect of EdgP that could be related to TRPV1 activity
and its possible role as a TRPV1 antagonist. However, this
assumption still needs to be veriﬁed.
The LD50 was used as reference for the choice of doses
of this work. The doses corresponded to 1/10 (75mg/kg),
1/5 (150mg/kg), and 1/2.5 (300mg/kg) of LD50 and were
lower than the doses used on previous studies [3]. In the
rota-rod test, EDgP caused a minor, but signiﬁcant, eﬀect
on motor coordination of mice treated with the highest
dose (300mg/kg) at 30 minutes, but not at the two other
time points (60 and 120 minutes), pointing to a transient
impairment of motility in mice.
In conclusion, the data presented in this study showed
that EDgP exerts a nondose-dependent antinociceptive
activity, as displayed by diﬀerent algesiometric tests, and
also suggest a possible anti-inﬂammatory eﬀect. Moreover,
this work corroborates the ﬁndings of previous researches
that demonstrated the analgesic activity of other parts of
D. grandiﬂora. However, further studies are necessary to
elucidate the mechanism behind the observed eﬀects.
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